• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

程序性死亡配体1调控成釉细胞瘤的生长和复发。

Programmed death-ligand 1 regulates ameloblastoma growth and recurrence.

作者信息

Zhang Linzhou, Lin Hao, Liang Jiajie, Liu Xuanhao, Zhang Chenxi, Man Qiwen, Li Ruifang, Zhao Yi, Liu Bing

机构信息

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, China.

Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, China.

出版信息

Int J Oral Sci. 2025 Apr 16;17(1):29. doi: 10.1038/s41368-025-00364-w.

DOI:10.1038/s41368-025-00364-w
PMID:40240323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12003687/
Abstract

Tumor cell-intrinsic programmed death-ligand 1 (PD-L1) signals mediate tumor initiation, progression and metastasis, but their effects in ameloblastoma (AM) have not been reported. In this comprehensive study, we observed marked upregulation of PD-L1 in AM tissues and revealed the robust correlation between elevated PD-L1 expression and increased tumor growth and recurrence rates. Notably, we found that PD-L1 overexpression markedly increased self-renewal capacity and promoted tumorigenic processes and invasion in hTERT-AM cells, whereas genetic ablation of PD-L1 exerted opposing inhibitory effects. By performing high-resolution single-cell profiling and thorough immunohistochemical analyses in AM patients, we delineated the intricate cellular landscape and elucidated the mechanisms underlying the aggressive phenotype and unfavorable prognosis of these tumors. Our findings revealed that hTERT-AM cells with upregulated PD-L1 expression exhibit increased proliferative potential and stem-like attributes and undergo partial epithelial‒mesenchymal transition. This phenotypic shift is induced by the activation of the PI3K-AKT-mTOR signaling axis; thus, this study revealed a crucial regulatory mechanism that fuels tumor growth and recurrence. Importantly, targeted inhibition of the PD-L1-PI3K-AKT-mTOR signaling axis significantly suppressed the growth of AM patient-derived tumor organoids, highlighting the potential of PD-L1 blockade as a promising therapeutic approach for AM.

摘要

肿瘤细胞内在的程序性死亡配体1(PD-L1)信号介导肿瘤的起始、进展和转移,但其在成釉细胞瘤(AM)中的作用尚未见报道。在这项综合性研究中,我们观察到AM组织中PD-L1显著上调,并揭示了PD-L1表达升高与肿瘤生长增加及复发率之间的密切相关性。值得注意的是,我们发现PD-L1过表达显著增加了hTERT-AM细胞的自我更新能力,并促进了致瘤过程和侵袭,而PD-L1的基因敲除则产生相反的抑制作用。通过对AM患者进行高分辨率单细胞分析和全面的免疫组化分析,我们描绘了复杂的细胞图谱,并阐明了这些肿瘤侵袭性表型和不良预后的潜在机制。我们的研究结果表明,PD-L1表达上调的hTERT-AM细胞表现出增加的增殖潜能和干细胞样特性,并经历部分上皮-间质转化。这种表型转变是由PI3K-AKT-mTOR信号轴的激活诱导的;因此,本研究揭示了一种促进肿瘤生长和复发的关键调控机制。重要的是,靶向抑制PD-L1-PI3K-AKT-mTOR信号轴显著抑制了AM患者来源的肿瘤类器官的生长,突出了阻断PD-L1作为AM一种有前景的治疗方法的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/48b7fd4333af/41368_2025_364_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/ae595b691dad/41368_2025_364_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/1e52204b737b/41368_2025_364_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/64073e1c6753/41368_2025_364_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/c32b89dec701/41368_2025_364_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/62dce41b2e21/41368_2025_364_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/aeb536b7f76e/41368_2025_364_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/48b7fd4333af/41368_2025_364_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/ae595b691dad/41368_2025_364_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/1e52204b737b/41368_2025_364_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/64073e1c6753/41368_2025_364_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/c32b89dec701/41368_2025_364_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/62dce41b2e21/41368_2025_364_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/aeb536b7f76e/41368_2025_364_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7951/12003687/48b7fd4333af/41368_2025_364_Fig7_HTML.jpg

相似文献

1
Programmed death-ligand 1 regulates ameloblastoma growth and recurrence.程序性死亡配体1调控成釉细胞瘤的生长和复发。
Int J Oral Sci. 2025 Apr 16;17(1):29. doi: 10.1038/s41368-025-00364-w.
2
PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.程序性死亡受体配体1(PD-L1)通过激活WIP和β-连环蛋白信号通路促进肿瘤生长和进展,并预示肺癌预后不良。
Cell Death Dis. 2020 Jul 6;11(7):506. doi: 10.1038/s41419-020-2701-z.
3
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.PD-1/PD-L1 阻断通过 PI3K/Akt/mTOR 信号通路挽救胃肠道间质瘤中耗竭的 CD8+ T 细胞。
Cell Prolif. 2019 May;52(3):e12571. doi: 10.1111/cpr.12571. Epub 2019 Feb 3.
4
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.PD-L1与p-AKT的共表达通过激活肿瘤细胞内的AKT/mTOR通路的PD-1/PD-L1轴,与弥漫性大B细胞淋巴瘤的不良预后相关。
Oncotarget. 2016 May 31;7(22):33350-62. doi: 10.18632/oncotarget.9061.
5
Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.程序性死亡配体 1 的表达与肝内胆管癌的预后相关。
Dig Dis Sci. 2020 Feb;65(2):480-488. doi: 10.1007/s10620-019-05787-0. Epub 2019 Aug 13.
6
The role of the PI3K/AKT/mTOR pathway in mediating PD-L1 upregulation during fibroblast transdifferentiation.PI3K/AKT/mTOR 通路在成纤维细胞转分化过程中调控 PD-L1 上调的作用。
Int Immunopharmacol. 2024 Dec 5;142(Pt B):113186. doi: 10.1016/j.intimp.2024.113186. Epub 2024 Sep 18.
7
Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.依维莫司(RAD001)联合程序性死亡受体 1(PD-1)阻断通过阻断磷脂酰肌醇 3-激酶(PI3K)/蛋白激酶 B(AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)/核糖体 S6 激酶 1(S6K1)通路增强宫颈癌的放射敏感性和程序性死亡配体 1(PD-L1)的表达。
Bioengineered. 2022 Apr;13(4):11240-11257. doi: 10.1080/21655979.2022.2064205.
8
Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.miR-424-5p 通过靶向 PD-L1 并调节 PTEN/PI3K/AKT/mTOR 信号通路抑制乳腺癌细胞中的肿瘤发生活性。
Life Sci. 2020 Oct 15;259:118239. doi: 10.1016/j.lfs.2020.118239. Epub 2020 Aug 10.
9
NK Cell Exosomes Alleviate PD-L1 Expression and Facilitate Tumor Immunity by Repressing PI3K-AKT-mTOR Signaling.自然杀伤细胞外泌体通过抑制PI3K-AKT-mTOR信号通路减轻PD-L1表达并促进肿瘤免疫。
Immunol Invest. 2025 Apr;54(3):382-395. doi: 10.1080/08820139.2024.2445608. Epub 2025 Jan 2.
10
PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.PD-L1 通过激活 PI3K/AKT 通路诱导鼻咽癌细胞发生上皮-间充质转化。
Oncol Res. 2019 Jul 12;27(7):801-807. doi: 10.3727/096504018X15446984186056. Epub 2019 Apr 12.

本文引用的文献

1
High expression of PD-L1 on conventional dendritic cells in tumour-draining lymph nodes is associated with poor prognosis in oral cancer.肿瘤引流淋巴结中常规树突状细胞上 PD-L1 的高表达与口腔癌预后不良相关。
Cancer Immunol Immunother. 2024 Jul 2;73(9):165. doi: 10.1007/s00262-024-03754-x.
2
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.PD-1/PD-L1 轴:在免疫调节、癌症进展和转化应用中的意义。
J Mol Med (Berl). 2024 Aug;102(8):987-1000. doi: 10.1007/s00109-024-02463-3. Epub 2024 Jun 27.
3
Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine.
关于液体活检中细胞外囊泡促进检验医学发展的共识声明。
Clin Chem Lab Med. 2024 Jun 19;63(3):465-482. doi: 10.1515/cclm-2024-0188. Print 2025 Feb 25.
4
Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma.单细胞转录组学揭示细胞图谱,并鉴定出导致成釉细胞瘤复发的循环肿瘤细胞。
Int J Oral Sci. 2024 Feb 29;16(1):21. doi: 10.1038/s41368-024-00281-4.
5
Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.新辅助 BRAF 靶向治疗下颌骨造釉细胞瘤:一种器官保留方法。
J Natl Cancer Inst. 2024 Apr 5;116(4):539-546. doi: 10.1093/jnci/djad232.
6
Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.精准医学时代晚期成釉细胞瘤的治疗选择:简要综述。
Oral Oncol. 2023 Nov;146:106585. doi: 10.1016/j.oraloncology.2023.106585. Epub 2023 Oct 8.
7
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.PI3K/AKT/mTOR 信号转导通路与癌症的靶向治疗。
Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6.
8
Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses.转移性腺瘤或造釉细胞瘤性癌?一例基因突变分析病例报告。
BMC Oral Health. 2023 Aug 12;23(1):563. doi: 10.1186/s12903-023-03259-6.
9
PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.PD-1 携带于小细胞外囊泡中导致口腔鳞状细胞癌转移。
J Dent Res. 2023 Jul;102(7):795-805. doi: 10.1177/00220345231165209. Epub 2023 May 29.
10
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating.抗 PD-1/L1 单药治疗 31 种癌症的客观缓解率全景:系统评价和新型生物标志物研究。
Cancer Immunol Immunother. 2023 Jul;72(7):2483-2498. doi: 10.1007/s00262-023-03441-3. Epub 2023 Apr 6.